The Inflation Reduction Act's drug pricing provisions represent the most significant change to pharmaceutical pricing policy in the history of Medicare — authorizing CMS to directly negotiate drug prices for a subset of high-expenditure Part D and Part B drugs, capping Medicare beneficiary out-of-pocket costs at $2,000 annually, and imposing inflation rebate requirements on drug price increases exceeding inflation. The first ten drugs subject to CMS negotiation were announced in 2023 with negotiated prices effective in 2026. The commercial implications for payers, PBMs, and distributors are significant — lower negotiated prices reduce PBM rebate revenue, change formulary dynamics, and reshape the specialty drug economics that underpin the financial models of CVS Caremark, OptumRx, and Express Scripts.
Topics Covered
• IRA Drug Negotiation Mechanics
• Negotiated Drug Prices and Impact
• PBM Revenue Implications
• Formulary Strategy Under IRA
• Biosimilar Promotion
• Price Transparency Requirements
• Pharmaceutical Manufacturer Response
• Outlook 2026-2030
Table of Contents
1. Executive Summary
2. Market and Policy Overview
3. IRA Drug Negotiation Mechanics
4. Negotiated Drug Prices and Impact
5. PBM Revenue Implications
6. Formulary Strategy Under IRA
7. Biosimilar Promotion
8. Price Transparency Requirements
9. Pharmaceutical Manufacturer Response
10. Outlook 2026-2030
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Policy and Market Overview 2025
Table 2. IRA Drug Negotiation Mechanics
Table 3. Negotiated Drug Prices and Impact
Table 4. PBM Revenue Implications
Table 5. Formulary Strategy Under IRA
Table 6. Biosimilar Promotion
Table 7. Price Transparency Requirements
Table 8. Pharmaceutical Manufacturer Response
Table 9. Outlook 2026-2030
Table 10. Leading Companies — Strategy and Response 2025
Table 11. Regulatory Timeline and Key Dates
Table 12. Key Risks and Mitigation Strategies
Companies Profiled
AbbVie
Bristol-Myers Squibb
CVS Caremark
Express Scripts
Humana Pharmacy
Johnson & Johnson
Merck
OptumRx
Pfizer
